[1]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4-8.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4-8.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
点击复制

表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
39
期数:
2015年第1期
页码:
4-8
栏目:
出版日期:
2015-01-25

文章信息/Info

Title:
The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients
作者:
郭坤1;  高蕊1;  于燕2;  刘岩1;  杨爱民1
1. 西安交通大学第一附属医院核医学科, 西安, 710061;
2. 西安交通大学医学院公共卫生学院, 西安, 710061
Author(s):
Guo Kun1;  Gao Rui1;  Yu Yan2;  Liu Yan1;  Yang Aimin1
Department of Nuclear Medicine, the First Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710061, China
关键词:
甲状腺功能亢进症; 碘放射性同位素; 受体; 表皮生长因子; 预后
Keywords:
Hyperthyroidism; Iodine radioisotopes; Receptor;  epidermal growth factor; Prognosis
DOI:
10.3760/cma.j.issn.1673-4114.2015.01.003
摘要:
目的 探讨甲状腺功能亢进症(简称甲亢)组织中表皮生长因子受体(EGFR)基因相对表达与131I治疗预后的关系。方法 入组拟行131I治疗的59例Graves甲亢患者作为实验组,平均年龄(46.46±12.95)岁,其中男性16例、女性43例;正常对照组27名,平均年龄(44.66±10.86)岁,其中男性6名、女性21名。入选者采用细针穿刺法获取甲状腺组织,应用荧光实时定量PCR法检测甲亢组织及正常甲状腺组织中EGFR基因的相对表达水平,采用t检验、方差分析及多因素分析探讨EGFR基因相对表达水平与131I治疗预后的关系。结果 EGFR基因在正常甲状腺组织及Graves甲亢组织中都有不同程度的表达;甲亢组织中EGFR的相对表达水平明显高于正常甲状腺组织(1.752±0.660 vs.0.859±0.125,t=4.328,P<0.001)。59例Graves甲亢患者经131I治疗6个月后,失访8例,其中,甲状腺功能减退症(简称甲减)占39.2%(20/51)、完全缓解占41.2%(21/51)、未愈占19.6%(10/51),甲亢治愈率(甲减+完全缓解)为80.4%。未愈组EGFR相对表达水平显著高于治愈组(甲减+完全缓解)(8.092±3.887 vs.1.383±0.160,t=7.647,P<0.001);未愈组(8.092±3.887) EGFR相对表达水平高于完全缓解组(1.487±0.479)和甲减组(0.968±0.180)(t=7.364和8.027,P<0.001)。Logistic回归分析显示:口服131I剂量(OR=3.456)、甲状腺质量(OR=3.853)及EGFR相对表达水平(OR=1.423)是甲亢患者131I治疗后影响治疗效果的主要因素。结论 EGFR基因的相对表达可能是预测甲亢131I治疗近期疗效及预后的指标。
Abstract:
Objective To study the relationship between the epidermal growth factor receptor (EGFR)mRNA expression and the efficacy of 131I treatment in hyperthyroidism patients. Methods Fine needle biopsies of 59[the male to female ratio was 16:43; mean age was(46.46±12.95) years old] Graves disease patients and 27[the male to female ratio was 6:21; mean age was (44.66±10.86) years old] normal volunteers were collected. The mRNA expression of EgFR was detected by real-time polymerase chain reaction before treatment. Ttest, analysis of variance and multivariate logistic regression analysis were applied to analyze the relationship between EGFR mRNA expression and the efficacy of 131I treatment.Results Compared with normal group, the mRNA expression level of EgFR was significantly higher in Graves disease patients (1.752±0.660 vs. 0.859±0.125, t=4.328, P<0.001). Six months after 131I treatment,except 8 cases were lost in following up, all of the remain 51 eligible evaluated patients were relieived from hyperthyroidism. Among them, 80.4% of patients was cured, 39.2% (20/51) became hypothyroid, 41.2%(21/51) became euthyroid, and 19.6% (10/51) remained hyperthyroid. The EGFR mRNA expression was significantly higher in uncured group than in cured group (8.092±3.887 vs. 1.383±0.160,t=7.647, P<0.001). The EGFR mRNA expression was significantly higher in uncured group(8.092±3.887) than in euthyroid (1.487±0.479)or hypothyroid group(0.968±0.180)(t=7.364 and 8.027, P<0.001). Multiple logistic regression revealed that the radioiodine dosage(OR=3.456), thyroid weight(OR=3.853) and EGFR mRNA expression (OR=1.423) was related to the efficacy of 131I treatment. Conclusion EGFR mRNA expression may be used in evaluating the prognosis of hyperthyroidism patients after 131I treatment.

参考文献/References:

[1] Nygaard B,Hegedüs L,Gervil M,et al.Influence of comoensated radioiodine therapy on thyroidvolume and incidence of hypothyroidism in Graves’disease[J].J Intern Med,1995,238(6):491-497.
[2] Farkasova T,Gurska S,Witkovsky V,et al.Significance of amino acid substitution variants of DNA repair genes in radiosusceptibility of cervical cancer patients: a pilot study[J].Neoplasma,2008,55(4):330-337.
[3] Wang H,Zhu L,Gao J,et al.Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells[J].Oncol Rep,2015,33(1):403-412.
[4] Jorissen RN,Walker F,Pouliot N,et al.Epidermal growth factor receptor:mechanisms of activation and signalling[J].Exp Cell Res,2003,284(1):31-53.
[5] Toulany M,Kasten-Pisula U,Brammer I,et al.Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair[J].Clin Cancer Res,2006,12(13):4119-4126.
[6] Meijer TW,Kaanders JH,Span PN,et al.Targeting hypoxia,HIF-1,and tumor glucose metabolism to improve radiotherapy efficacy[J].Clin Cancer Res,2012,18(20):5585-5594.
[7] 中华医学会内分泌学分会《 中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南-甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882.
[8] Asami K,Atagi S.Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer[J].World J Clin Oncol, 2014,5(4):646-659.
[9] Marti U,Ruchti C,K?mpf J,et al.Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues[J].Thyroid,2001,11(2):137-145.
[10] Bussink J,van der Kogel AJ,kaanders JH.Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer[J].Lancet Oncol,2008,9(3):288-296.
[11] Nijkamp MM,Span PN,Terhaard CH,et al.Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial[J].Eur J Cancer,2013,49(15):3202-3209.
[12] Ang KK,Berkey BA,Tu X,et al.Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J].Cancer Res,2002,62(24):7350-7356.
[13] Maurizi M,Almadori G,Ferrandina G,et al.Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma[J].Br J Cancer,1996,74(8):1253-1257.
[14] Huang SM,Harari PM.Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas:inhibition of damage repair,cell cycle kinetics,and tumor angiogenesis[J].Clin Cancer Res,2000,6(6):2166-2174.
[15] Chiovato L,Fiore E,Vitti P,et al.Outcome of thyroid function in Graves’ patients treated with radioiodine:role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage[J].J Clin Endocrinol Metab,1998,83(1):40-46.
[16] 谭建,王澎,张丽娟,等.131I治疗Graves病后早发甲低相关因素的综合分析[J].中华核医学杂志,2005,25(6):325-328.
[17] Zanotti-Fregonara P,Hindié E.On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer[J].Eur J Nucl Med Mol Imaging,2010,37(12):2264-2266.
[18] Erem C,Kandemir N,Hacihasanoglu A,et al.Radioiodine treatment of hyperthyroidism:prognostic factors affecting outcome[J].Endocrine,2004,25(1):55-60.

相似文献/References:

[1]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[4]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[7]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[8]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[9]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
　Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[10]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
　MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[15]王春梅,王雪梅.131I治疗甲亢的现状和研究进展[J].国际放射医学核医学杂志,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
　WANG Chun-mei,WANG Xue-mei.The development and current status of 131I treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
[16]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
　SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):143.
[17]冯菲,赵德善.131I治疗青少年儿童甲状腺功能亢进症[J].国际放射医学核医学杂志,2009,33(3):171.[doi:10.3760/cma.j.issn.1673-4114.2009.03.011]
　FENG Fei,ZHAO De-shan.The treatment of hyperthyroidism in adolescents and children with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):171.[doi:10.3760/cma.j.issn.1673-4114.2009.03.011]
[18]汤建林,李玉莹,高柳艳,等.甲状腺功能亢进症治疗方法的比较和选择[J].国际放射医学核医学杂志,2009,33(3):175.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
　TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.The methods and options of the treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):175.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
[19]潘香颖,李慧贞.甲状腺功能亢进症伴肝功能受损的131I治疗疗效[J].国际放射医学核医学杂志,2009,33(3):179.[doi:10.3760/cma.j.issn.1673-4114.2009.03.013]
[20]王长修.甲状腺功能亢进症患者再次131I治疗的给药剂量对比研究[J].国际放射医学核医学杂志,2009,33(3):182.[doi:10.3760/cma.j.issn.1673-4114.2009.03.016]

备注/Memo

备注/Memo:
收稿日期:2014-11-06。
基金项目:国家自然科学基金(81172598);陕西省自然科学基金(2010JM4037)
通讯作者:杨爱民,Email:yangaimin@mail.xjtu.edu.cn
更新日期/Last Update: 1900-01-01